BRCA1 deficient cells are highly sensitive to PARP and DNA methyltransferase inhibition in comparison with wild-type BRCA1 cells, resulting in clinical trials in breast cancer patients to test the efficiency of these drugs (Dobrovic and Simpfendorfer, 1997). This evidence concerns the gene BRCA1 and breast cancer.